CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ALNY, mapped to public ticker ALNY (CIK 0001178670). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗
Trial → FilingALNY35% conf

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →